Bioavailability Study of Clonazepam Tablets Under Fasting Conditions - Full Text View

Sponsor:	Par Pharmaceutical, Inc.
Collaborator:	Cetero Research
Information provided by:	Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier:	NCT00652639

Purpose

To compare the single-dose bioavailability of Clonazepam tablets 1 mg and Klonopin tablets 1 mg

Condition	Intervention	Phase
To Determine Bioequivalence Under Fasting Conditions	Drug: Clonazepam Drug: Klonopin	Phase I

Study Type:	Interventional
Study Design:	Randomized, Open Label, Crossover Assignment, Bio-equivalence Study
Official Title:	Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Kali's Clonazepam Tablets 1 mg With That of Klonopin Tablets 1 mg in Healthy Adult Subjects Under Fasting Conditions.

Resource links provided by NLM:

Drug Information available for: Clonazepam

U.S. FDA Resources

Further study details as provided by Par Pharmaceutical, Inc.:

Primary Outcome Measures:

Rate and Extend of Absorption [ Time Frame: 24 Hours ] [ Designated as safety issue: No ]

Enrollment:	32
Study Start Date:	February 2004
Study Completion Date:	April 2004
Primary Completion Date:	March 2004 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental Subjects received the kali formulated products under fasting conditions	Drug: Clonazepam Tablets, 1 mg, single-dose
B: Active Comparator Subjects received the Roche formulated products under fasting conditions	Drug: Klonopin tablets, 1 mg, single-dose

Detailed Description:

To compare the single -dose bioavailability of kali's Clonazepam tablets 1 mg with that of Klonopin tablets 1 mg by Roche pharmaceuticals following a single oral dose under fasting conditions.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

All subjects selected for this study will be alt least 18 years of age.Females must be of non- childbearing potential (postmenopausal for alt least 6 months or surgically sterile)
Each subject shall be given a general physical examination within 28 days of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
Each female subject will be given a serum pregnancy test as part of the pre-study process.
At the end of the study, the subjects will have an exit evaluation consisting of interim history, global evaluation, and clinical laboratory measurements.
Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trail for clinical laboratory.
Clinical laboratory measurements will include the following:
Hematology: hemoglobin, hematocrit, red blood cell count (with differential)
Clinical Chemistry: creatinine, BUN, glucose, SGOT/ AST, SGPT/ALT, bilirubin, and alkaline phosphate.
Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood and cells.
HIV Screen: (Pre-study only)
Hepatitis-B, C Screen: (Pre-study only)
Drugs of Abuse Screen: (Pre-study at check -in each dosing period)
Electrocardiograms of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.

Exclusion Criteria:

Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis epilepsy, asthma, (during pat 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
Subjects whose clinical laboratory test values are outside the normal range may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
Subjects who have a history of allergic response to the class of drug being tested should excluded form the study.
All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and check in each dosing period. Subjects found to have urine concentration of any of the tested drugs will not be allowed to participate.
Subjects should not have donated blood and/plasma for at least thirty (30) days prior to the first dosing of the study
Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
Female subjects with childbearing potential will not be allowed to participate.
All female subjects will be screened for pregnancy at check in each study period.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00652639

Sponsors and Collaborators

Par Pharmaceutical, Inc.

Cetero Research

Investigators

Principal Investigator:	Irwin Plisco	Cetero Research
Study Director:	Gary Shillito	Cetero Research

More Information

No publications provided

Responsible Party:	Par Pharmaceutical, Inc. ( Dr. Alfred Elvin/ Director Biopharmaceutics )
Study ID Numbers:	B043201
Study First Received:	April 1, 2008
Last Updated:	April 3, 2008
ClinicalTrials.gov Identifier:	NCT00652639 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Par Pharmaceutical, Inc.:

bioequivalence, Clonazepam tablets, fasting

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
GABA Modulators
Therapeutic Uses
Physiological Effects of Drugs

Clonazepam
GABA Agents
Central Nervous System Agents
Pharmacologic Actions
Anticonvulsants

ClinicalTrials.gov processed this record on November 20, 2009